Akèy › Limfòm Burkitt › New York
Etid klinik pou Limfòm Burkitt nan New York
20 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan New York.
Vil nan New York
- New York City14 etid
- Buffalo8 etid
- Greenburgh7 etid
- The Bronx6 etid
- Queens6 etid
- Albany4 etid
- Syracuse4 etid
- Rochester4 etid
Tèks ofisyèl etid la (Anglè)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- NYU Langone Hospital - Long Island, Mineola
- ak 9 plis
Ap rekriteFaz 2
366 Days – 46 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Roswell Park Cancer Institute, Buffalo
- Northwell Health/Center for Advanced Medicine, Lake Success
- North Shore University Hospital, Manhasset
- ak 4 plis
Ap rekriteFaz 3
Laj 18 a 39 · Tout sèks · Mizajou Oct 2, 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Northwell Health/Center for Advanced Medicine, Lake Success
- North Shore University Hospital, Manhasset
- Long Island Jewish Medical Center, New Hyde Park
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Albany Medical Center, Albany
- Roswell Park Cancer Institute, Buffalo
- The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park
- ak 7 plis
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- David H. Koch Center for Cancer Care, New York
- Montefiore Medical Center PRIME, The Bronx
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 3
Laj 1 ak plis · Tout sèks · Mizajou Sep 17, 2026 · NCT07223021Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Memorial Sloan Kettering Cancer Center ( Site 1010), New York
- New York Medical College ( Site 1023), Valhalla
Ap rekriteFaz 1/2
6 Months – 25 Years · Tout sèks · Mizajou Sep 17, 2026 · NCT06395103A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
- The Mount Sinai Hospital, New York
Ap rekriteFaz 1
Laj 0 a 18 · Tout sèks · Mizajou Sep 16, 2026 · NCT06173518Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Columbia University Irving Medical Center/New York Presbyterian Hospital, New York
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 8, 2026 · NCT03666000A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- NYU Langone Hospital - Long Island, Mineola
- ak 7 plis
Ap rekriteFaz 2
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Albany Medical Center, Albany
- Maimonides Medical Center, Brooklyn
- Roswell Park Cancer Institute, Buffalo
- ak 12 plis
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
- Research Site, New York
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT06137118Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- New York Medical College, Valhalla
Ap rekriteFaz 1/2
Laj 13 a 90 · Tout sèks · Mizajou Aug 6, 2026 · NCT06533579Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
- New York Medical Center, Valhalla
Ap rekriteFaz 1/2
Laj 12 a 70 · Tout sèks · Mizajou Apr 15, 2026 · NCT04491370Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 2
Laj 18 a 54 · Tout sèks · Mizajou Mar 17, 2026 · NCT06918431Study of SGR-1505 in Mature B-Cell Neoplasms
- Roswell Park Comprehensive Cancer Center, Buffalo
- Weill Cornell, New York
- Montefiore Medical Center, The Bronx
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Feb 13, 2026 · NCT05544019ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
- Roswell Park Comprehensive Cancer Center, Buffalo
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 4, 2025 · NCT03595917Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
- Roswell Park Comprehensive Cancer Center, Buffalo
- Memorial Sloan Kettering Cancer Center (MSKCC) David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Ap rekriteFaz 1/2
Laj 15 a 50 · Tout sèks · Mizajou Sep 9, 2025 · NCT04150497Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
- New York Medical College, Valhalla
Ap rekriteFaz 2
Laj 3 a 31 · Tout sèks · Mizajou Aug 8, 2025 · NCT02393157The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Roswell Park Cancer Institute, Buffalo
Ap rekriteFaz 2
Laj 1 a 25 · Tout sèks · Mizajou May 4, 2025 · NCT03509961Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.